Mariner’s Scinai Immunotherapeutics SCNI Stock Holding History

Mariner’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-566	Closed	-$525K	–	746
2019 Q4	$525K	Buy	+566	New	+$348K	0.01%	606
2019 Q1	–	Sell	-270	Closed	-$129K	–	1052
2018 Q4	$129K	Buy	+270	New	+$146K	﹤0.01%	796

Other funds holding SCNI

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mariner's SCNI Position: Q1 2020 in Review

Mariner sold out of Scinai Immunotherapeutics (SCNI) in Q1 2020, closing a stake of 566 shares — an estimated $525K sold.

Mariner first reported a position in SCNI in Q4 2018 and held it in 2 quarters. The position peaked at $525K in Q4 2019. 8 funds tracked by Wall St. Rank hold SCNI as of Q1 2020.

Mariner reported no remaining Scinai Immunotherapeutics position as of Q1 2020 after selling out during the quarter.
Mariner sold 566 Scinai Immunotherapeutics shares in Q1 2020, an estimated $525K.
Mariner first reported a position in Scinai Immunotherapeutics in Q4 2018 and held it in 2 quarters.
Mariner's Scinai Immunotherapeutics position peaked at $525K in Q4 2019.
8 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2020.

Based on Mariner's 13F filing for Q1 2020, filed 14 May 2020.